Cellular reprogramming and cancer development

International Journal of Cancer

Volumn 132, Issue 6, 2013, Pages 1240-1248

  Semi, Katsunori ^a,b   Matsuda, Yutaka ^a   Ohnishi, Kotaro ^a   Yamada, Yasuhiro ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

cancer epigenetics; iPS cells; reprogramming

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CPG OLIGODEOXYNUCLEOTIDE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE; OCTAMER TRANSCRIPTION FACTOR 4; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENETICS; CANCER MODEL; CANCER RESEARCH; CANCER RISK; CANCER TRANSPLANTATION; CARCINOGENESIS; CATALYSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL NUCLEUS TRANSPLANTATION; CELL STRUCTURE; CYTOLOGY; DISEASE ACTIVITY; DNA METHYLATION; DNA MODIFICATION; DNMT1 GENE; ENZYME ACTIVITY; EPIGENETIC REPRESSION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PROCEDURES; GENOME IMPRINTING; GENOMIC INSTABILITY; HUMAN; IGF2 GENE; IGF2R GENE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; ONCOGENE MYC; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, RAS; GENOMIC IMPRINTING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS; NUCLEAR REPROGRAMMING; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84872907647     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27963     Document Type: Article

References (102)

1. Feinberg AP, Tycko B,. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-153. (Pubitemid 38198742)
2. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428. (Pubitemid 34587077)
3. Jaenisch R, Bird A,. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 (Suppl): 245-254. (Pubitemid 36278835)
4. Linhart HG, Lin H, Yamada Y, et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 2007; 21: 3110-3122. (Pubitemid 350223528)
5. Feinberg AP, Vogelstein B,. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92. (Pubitemid 13154475)
6. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11: 6883-6894.
7. Jeanpierre M, Turleau C, Aurias A, et al. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Human Mol Genet 1993; 2: 731-735. (Pubitemid 23197518)
8. Ji W, Hernandez R, Zhang XY, et al. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mut Res 1997; 379: 33-41. (Pubitemid 27394232)
9. Chen RZ, Pettersson U, Beard C, et al. DNA hypomethylation leads to elevated mutation rates. Nature 1998; 395: 89-93. (Pubitemid 28420236)
10. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455. (Pubitemid 36444319)
11. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 489-492. (Pubitemid 36444330)
12. Brueckner B, Lyko F,. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 2004; 25: 551-554. (Pubitemid 39371143)
13. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995; 81: 197-205.
14. Cormier RT, Dove WF,. Dnmt1N/+ reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice independently of p53 but demonstrates strong synergy with the modifier of Min 1(AKR) resistance allele. Cancer Res 2000; 60: 3965-3970. (Pubitemid 32204593)
15. Eads CA, Nickel AE, Laird PW,. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res 2002; 62: 1296-1299. (Pubitemid 34407781)
16. Yamada Y, Jackson-Grusby L, Linhart H, et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 2005; 102: 13580-13585. (Pubitemid 41420891)
17. Lin H, Yamada Y, Nguyen S, et al. Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol 2006; 26: 2976-2983.
18. Bartolomei MS,. Epigenetics: role of germ cell imprinting. Adv Exp Med Biol 2003; 518: 239-245. (Pubitemid 36760289)
19. Reik W, Walter J,. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001; 2: 21-32. (Pubitemid 33674766)
20. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993; 362: 749-751. (Pubitemid 23125978)
21. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature 1993; 362: 747-749. (Pubitemid 23125977)
22. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005; 307: 1976-1978. (Pubitemid 40404709)
23. De Souza AT, Yamada T, Mills JJ, et al. Imprinted genes in liver carcinogenesis. FASEB J 1997; 11: 60-67. (Pubitemid 27076325)
24. Kobatake T, Yano M, Toyooka S, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004; 12: 1087-1092.
25. Trouillard O, Aguirre-Cruz L, Hoang-Xuan K, et al. Parental 19q loss and PEG3 expression in oligodendrogliomas. Cancer Genet Cytogenet 2004; 151: 182-183. (Pubitemid 38692820)
26. DeBaun MR, Niemitz EL, McNeil DE, et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 2002; 70: 604-611. (Pubitemid 34177916)
27. Holm TM, Jackson-Grusby L, Brambrink T, et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005; 8: 275-285. (Pubitemid 41443413)
28. Jenuwein T, Allis CD,. Translating the histone code. Science 2001; 293: 1074-1080. (Pubitemid 32758077)
29. Cao R, Zhang Y,. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-164. (Pubitemid 38520143)
30. Levine SS, Weiss A, Erdjument-Bromage H, et al. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 2002; 22: 6070-6078. (Pubitemid 34857827)
31. Shao Z, Raible F, Mollaaghababa R, et al. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 1999; 98: 37-46. (Pubitemid 29331194)
32. Dellino GI, Schwartz YB, Farkas G, et al. Polycomb silencing blocks transcription initiation. Mol Cell 2004; 13: 887-893. (Pubitemid 38438483)
33. Tachibana M, Sugimoto K, Fukushima T, et al. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001; 276: 25309-25317.
34. Rice JC, Briggs SD, Ueberheide B, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 2003; 12: 1591-1598. (Pubitemid 38037025)
35. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mut Res 2008; 647: 21-29.
36. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
37. Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004; 428: 337-341. (Pubitemid 38418806)
38. Kondo Y, Shen L, Suzuki S, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007; 37: 974-983. (Pubitemid 47399927)
39. Fuks F,. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005; 15: 490-495. (Pubitemid 41262404)
40. Klose RJ, Bird AP,. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31: 89-97. (Pubitemid 43221841)
41. Gurdon JB,. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 1962; 10: 622-640.
42. Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385: 810-813. (Pubitemid 27106068)
43. Wakayama T, Perry AC, Zuccotti M, et al. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 1998; 394: 369-374. (Pubitemid 28373832)
44. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872. (Pubitemid 350138099)
45. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676. (Pubitemid 44233629)
46. Koche RP, Smith ZD, Adli M, et al. Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell 2011; 8: 96-105.
47. Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008; 454: 49-55. (Pubitemid 351931978)
48. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26: 795-797. (Pubitemid 351961456)
49. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
50. Yamanaka S,. A fresh look at iPS cells. Cell 2009; 137: 13-17.
51. Varum S, Rodrigues AS, Moura MB, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PloS One 2011; 6: e20914.
52. Panopoulos AD, Yanes O, Ruiz S, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 2012; 22: 168-177.
53. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
54. Krizhanovsky V, Lowe SW,. Stem cells: the promises and perils of p53. Nature 2009; 460: 1085-1086.
55. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-391. (Pubitemid 28507326)
56. Donovan PJ,. High Oct-Ane fuel powers the stem cell. Nat Genet 2001; 29: 246-247. (Pubitemid 33096444)
57. Gidekel S, Pizov G, Bergman Y, et al. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003; 4: 361-370. (Pubitemid 37491097)
58. Hochedlinger K, Yamada Y, Beard C, et al. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005; 121: 465-477. (Pubitemid 40692305)
59. Lin CY, Loven J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56-67.
60. Kim J, Chu J, Shen X, et al. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132: 1049-1061. (Pubitemid 351381745)
61. Amit M, Carpenter MK, Inokuma MS, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 2000; 227: 271-278.
62. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147. (Pubitemid 28516247)
63. Hiyama E, Hiyama K,. Telomere and telomerase in stem cells. British journal of cancer 2007; 96: 1020-1024. (Pubitemid 46608315)
64. Sperger JM, Chen X, Draper JS, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci USA 2003; 100: 13350-13355. (Pubitemid 37444745)
65. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507. (Pubitemid 351601215)
66. Wong DJ, Liu H, Ridky TW, et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008; 2: 333-344. (Pubitemid 351455242)
67. Calvanese V, Horrillo A, Hmadcha A, et al. Cancer genes hypermethylated in human embryonic stem cells. PloS One 2008; 3: e3294.
68. Ben-David U, Benvenisty N,. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011; 11: 268-277.
69. Ushijima T,. Epigenetic field for cancerization. J Biochem Mol Biol 2007; 40: 142-150. (Pubitemid 46515191)
70. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
71. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
72. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471: 68-73.
73. Pera MF,. Stem cells: The dark side of induced pluripotency. Nature 2011; 471: 46-47.
74. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
75. Pick M, Stelzer Y, Bar-Nur O, et al. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells 2009; 27: 2686-2690.
76. Stadtfeld M, Apostolou E, Akutsu H, et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010; 465: 175-181.
77. Jirtle RL,. Genomic imprinting and cancer. Exp Cell Res 1999; 248: 18-24. (Pubitemid 29393925)
78. Lim DH, Maher ER,. Genomic imprinting syndromes and cancer. Adv Genet 2010; 70: 145-175.
79. Nakagawa M, Takizawa N, Narita M, et al. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA 2010; 107: 14152-14157.
80. Maekawa M, Yamaguchi K, Nakamura T, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature 2011; 474: 225-229.
81. Ramos-Mejia V, Munoz-Lopez M, Garcia-Perez JL, et al. iPSC lines that do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability. Cell Res 2010; 20: 1092-1095.
82. Foster KW, Liu Z, Nail CD, et al. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 2005; 24: 1491-1500. (Pubitemid 40396079)
83. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381-384.
84. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
85. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
86. Fusaki N, Ban H, Nishiyama A, et al, Hasegawa M,. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 348-362.
87. Woltjen K, Hamalainen R, Kibschull M, et al. Transgene-free production of pluripotent stem cells using piggyBac transposons. Methods Mol Biol 2011; 767: 87-103.
88. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771-775.
89. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-953.
90. McKinnell RG, Deggins BA, Labat DD,. Transplantation of pluripotential nuclei from triploid frog tumors. Science 1969; 165: 394-396.
91. Hochedlinger K, Blelloch R, Brennan C, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004; 18: 1875-1885. (Pubitemid 39025097)
92. Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039-4042.
93. Kumano K, Arai S, Hosoi M, et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012; 119: 6234-6242.
94. Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122: 3502-3510.
95. Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natil Acad Sci USA 2010; 107: 40-45.
96. Sieber OM, Tomlinson SR, Tomlinson IP,. Tissue, cell and stage specificity of (epi)mutations in cancers. Nat Rev Cancer 2005; 5: 649-655. (Pubitemid 41081390)
97. Luo J, Solimini NL, Elledge SJ,. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
98. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822. (Pubitemid 44258912)
99. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956. (Pubitemid 41345211)
100. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441: 349-353. (Pubitemid 44050199)
101. Hochedlinger K, Jaenisch R,. Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature 2002; 415: 1035-1038. (Pubitemid 34193452)
102. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608-611.